Poly-L-Lactic Acid

In short: Poly-L-Lactic acid (PLLA/Sculptra) is a biostimulatory filler that triggers fibroblast activation and collagen neogenesis through synthetic polymer microparticles injected under the skin. It does not provide direct volume; It builds its own collagen over time. Duration of effect 2-3+ years (longest lasting filler). 3 sessions and massage protocol (Rule of 5s) are critical for success.

Description

Poly-L-Lactic acid (PLLA) is a synthetic, biodegradable polymer known under the trade names Sculptra (Galderma) and Sculptra Aesthetic, and consists of a macromolecule formed by chaining many molecules of the L-isomer of lactic acid (CH₃CHOHCOOH), which is naturally found in the body, with ester bonds. PLLA, instead of acting on classical fillers (such as hyaluronic acid, calcium hydroxyapatite) that directly provide volume in its external mechanism injected under the skin, is processed as a foreign body recognized by macrophages in the subcutaneous tissue and triggers fibroblast activation and endogenous collagen synthesis (collagen neogenesis). This biostimulator mechanism provides long-term (2-3 years or more) aesthetic improvement by initiating the body's own repair and thickening process instead of direct filler.

PLLA was first introduced to the medical field as absorbable surgical suture (Vicryl, PGA) in the 1960s. In 1999, the European Agency for Medicines Evaluation (EMA) approved Sculptra for the treatment of HIV-associated facial lipoatrophy (AIDS lipodystrophy); In 2004, the US Food and Drug Administration (FDA) approved Sculptra for the same medical indication; In 2009, the FDA approved Sculptra Aesthetic for the cosmetic indication (aged facial volumization). Over the past 15 years, PLLA biostimulator technology has advanced significantly—hyperdilution technique, ultrasound guided injection, and formulations that minimize macrophage response have been developed. Today, PLLA is the biostimulator of choice for deep volume loss (aging, health problems) and long-term facial rejuvenation.

Chemical Structure and Biomedical Mechanism

Chemical structure: PLLA is an α-hydroxy acid polymer synthesized by polycondensation reaction. Monomer unit, lactic acid (C₃H₆O₃) L-isomer; During polymerization, each monomer forms a long chain by connecting to the other via an ester bond (-COOC-). Result: -(CHCH₃-CO-O)-n repeating unit. PLLA is designed as a linear polymer, which creates its brittle structure — the non-crystalline (amorphous) form undergoes slow hydrolysis (chemical degradation) in water. The molecular weight is typically 200,000–400,000 Daltons—large enough that biological enzymes in the body do not break it down immediately. Particle size: In PLLA Sculptra formulation, average micron diameter 25–40 μm (micro); This size is optimal for macrophage phagocytosis—too small and enzymes break it down quickly, too large and the macrophage cannot take it up.

In vivo biodegradation (biological breakdown within the body): After injection, PLLA particles placed under the skin cause almost no pain; However, the body recognizes it as a foreign body. In the first 1–2 weeks, circulating macrophages (histiocytes, Langhans type giant cells) direct their attention to PLLA particles and take them in by phagocytosis and endocytosis. This phagocytic process triggers local inflammation—a mechanism similar to the classic foreign body granuloma. Local inflammation triggers fibroblast and myofibroblast activation as a result of the release of cytokines such as IL-1, TNF-α, and TGF-β. Fibroblasts increase collagen synthesis (type I and type III collagen) and extracellular matrix (ECM) production. In parallel, PLLA particles are hydrolyzed via ester bonds—the polymer breaks down into short oligomers and monomers over time (3–6 months). Final metabolite: lactic acid → acetyl-CoA → normal metabolic pathways (TCA cycle). PLLA, metabolized by macrophages, produces no systemic toxicity; It remains biologically “inert” — which is why it received FDA approval.

Collagen neogenesis mechanism: The main difference of PLLA is that it triggers long-term collagen construction in the hypodermal layer (under the dermis). The process is as follows: (1) Macrophage phagocytosis → local T-helper 2 (Th2) cytokine release; (2) Th2 cytokines (IL-4, IL-13) stimulate fibroblast progenitor and resident fibroblasts; (3) Stimulated fibroblasts produce type I collagen (provides resistance, elasticity) and type III collagen (provides softness, flexibility). The rate of type I collagen increases over time (after 6 months), while type III collagen appears in a shorter period (3–6 weeks). Collagen synthesis reaches peak levels within 6–12 weeks; During this period, skin thickening is observed. The newly synthesized collagen integrates into the dermal matrix in a similar way to natural collagen fibers — so its effect appears permanent.

Bulking curve — "lazy lift": The characteristic feature of PLLA is a subtle increase in volume immediately after injection, followed by a slowly increasing volume over months. Clinically: (1) First 1–3 days after injection: slight swelling and illusion of volume due to sterile water dilution (flood filler — “fluid filler” effect); (2) Within 2–3 weeks: swelling improves, volume returns to baseline; here patients may worry that "it didn't work"; (3) 6–12 weeks: collagen synthesis becomes evident, facial volume gradually increases; (4) 4–6 months: maximal volume increase is at its peak. Duration of effect: 2–3 years or longer (depending on dosimetry and patient variation). This "lazy" curve teaches patients that patience is required after the injection.

Sculptra: Product Features and Supply

Commercial product: Sculptra and Sculptra Aesthetic (Galderma, France) are the main providers of FDA-approved, PLLA filler. Each vial contains freeze-dried PLLA microparticles: 0.7 g (700 mg) micron particles in a typical dose vial. Sculptra must be reconstituted with sterile saline or distilled water, not as a solution. Liquid production type: Sculptra L (Liquid Sculptra) is the newer formulation, making it pre-prepared and ready for injection — but some centers still prefer freshly reconstituted PLLA (because of shelf life issues, risk of particle aggregation). In Türkiye, Sculptra is sourced and imported by Galderma distributors; The price is usually ₺2000–3500 per vial (depending on dollar fluctuation).

Alternative PLLA products: Apart from Sculptra, there are other PLLA biostimulators: Ellansé (Merz, Germany) — PLLA + CMC (carboxymethylcellulose) hybrid; Radiesse (Galderma) — calcium hydroxyapatite (CaHA), not PLLA but similar mechanism. However, "pure PLLA" Sculptra is considered standard.

Biomedical Use History: From Sutures to Fillers

Surgical suture era (1960s–1980s): PLLA was first introduced as absorbable surgical sutures. α-hydroxy acid polymers such as Vicryl (polyglactin 910) and PGA (polyglycolic acid) were products that surgeons requested as sutures that were slowly absorbed in the body and did not require re-operation. PLLA sutures have been widely used in areas such as muscle and bone repair and gastrointestinal surgery. This biomedical background provided high documentation of PLLA's safety profile—the body successfully metabolizes PLLA and there is no cumulative toxicity.

Transition to the field of medical aesthetics (1999–2009): In the late 1990s, researchers discovered that injecting PLLA microparticles under the skin could trigger fibroblast activation. In 1999, the European Agency for Medicines Evaluation (EMA) approved Sculptra for the treatment of HIV-associated facial lipoatrophy (circumoral, malar and temporal fossa volume loss). This approval opened PLLA to therapeutic use. In 2004, the FDA approved Sculptra for the same medical indication. In 2009, FDA approved Sculptra Aesthetic—for cosmetic indication (age-related facial volume loss, nasolabial fold deepening, malar hollowing). This historical development has confirmed the applicability of PLLA in both medical and aesthetic fields.

Clinic growth (2009–present): Over the last 15 years, the use of PLLA has become rapidly widespread in the field of aesthetic medicine. Technical developments (hyperdilution, ultrasound guide injection, thin cannula preferences) have reduced the rate of side effects and increased the success rate. Dermatologists, plastic surgeons and aesthetic medicine specialists have adopted PLLA as the standard biostimulator in their "panfacial rejuvenation" protocols. Today, PLLA is one of the most commonly used biostimulators in the world, forming the "big three" filler category with HA (hyaluronic acid) and CaHA (calcium hydroxyapatite).

Indications

Aesthetic indications:

• Panfacial volumization (middle-late age face): Facial volume loss due to aging. Typical areas: malar area (cheeks), temporal fossa (synchronous), nasolabial fold (nose-mouth line), marionette lines (mouth corner lines), mandibular outline (jaw line), frontal temporal area (forehead-temple)
• Deep dynamic lines and wrinkles: Deep wrinkles caused by volumetric loss instead of static lines. PLLA softens lines through underlay skin thickening
• Temporal fossa hollowing: Depression in the temple area — due to aging or hereditary factors. PLLA injection restores temple volume
• Mid-face right and lateral cheekbone ptosis: Lowering of the drooping point of the cheeks. PLLA provides a lifting effect by adding volume to the malar area.
• Hip and arm "jowl" deformity: Drooping down at the corner of the chin. PLLA provides contour improvement by adding volume below
• Skin tightening and mini-facelift-like effect: Skin texture and elasticity improve due to PLLA-triggered collagen synthesis, epidermal and dermal thickening. Total effect: subtle facelift-like face-lift look
• Volume loss around the lips and lip lines: Perioral area thinning. PLLA softens lip lines and pencil lines by thickening the tissue around the lips.

Medical indications:

• HIV-associated facial lipoatrophy (AIDS lipodystrophy): Facial volume loss as a side effect of antiretroviral therapy (ART). PLLA, FDA approved treatment (therapeutic indication)
• Post-liposuction deformities: Uncontoured or asymmetrical areas after fat suction. PLLA provides correction through tissue thickening
• Scar camouflage after healing: PLLA provides volumization and underlay equalization in areas such as depressed scars and acne scars.

Contraindications

• Use on lips and periorbital area: High risk of superficial injection — nodule formation possible. PLLA is not suitable for superficial areas
• Keloid tendency or abnormal scar healing: PLLA-triggered collagen synthesis may stimulate keloid-prone patients
• Active skin infection (acne, herpes, cellulitis): Risk of infection, failure and complications at the injection site
• Severe serositis or antiphospholipid syndrome: Autoimmune disorders may overreact to injection with PLLA particles
• Pregnancy and breastfeeding: Insufficient safety data; not recommended
• General: History of botulinum toxin allergy or hypersensitivity to PLLA/biostimulators

Session Protocol: Dilution, Technique and Massage

Number and interval of sessions: PLLA treatment is not a SOLITARY single session — it typically consists of 3 sessions. Interval between sessions: 4–6 weeks. Timing analysis: (1) 1st session: baseline PLLA injection; (2) 2nd session (after 4–6 weeks): monitoring the effect of the first session, injection into other areas if necessary; (3) 3rd session (4–6 weeks later): final refinement and completion. This three-session protocol is important for triggering maximal collagen neogenesis and minimizing the risk of unbalanced volume. Some physicians do a 4th or 5th session (for long-term maximal effect), but the standard is 3 sessions.

Reconstitution procedure — CRITICAL SECURITY ISSUE:

• Standard formulation: 0.7 g (700 mg) freeze-dried PLLA in one Sculptra vial; 5 mL sterile distilled water or sterile saline + 1 mL 1% lidocaine (local anesthetic) + optionally 0.3 mL sodium bicarbonate (pH adjustment). Result: 6.3 mL of ready-for-injection product, 111 mg/mL PLLA concentration.
• Dilution timing — 24 HOUR WAIT REQUIRED: After PLLA is mixed with sterile water, it must be kept for a minimum of 24 hours to ensure uniform distribution of the particles in the water. Immediate use concentrates the particles (risk of aggregation) and prevents passage through the fine cannula during injection (needle clogging). The 24-hour rest period ensures that the water absorbed by the PLLA particles disperses and uniform suspension occurs. Physician and patient awareness: if the 24-hour waiting period is violated, the risk of nodules increases dramatically.
• Hyperdilution technique (popular in the last decade): As an alternative to the conventional method, the physician may use 8–10 mL of sterile water (excluding 1 mL of lidocaine). Result: concentration of 70–80 mg/mL instead of 111 mg/mL. Advantages: (a) Finer particle distribution — reduced risk of nodules; (b) Injection into larger areas — more homogeneous distribution; (c) Lower local inflammation. Disadvantage: 24-hour waiting is still mandatory (can even be extended to 48 hours). Developed centers in Türkiye prefer hyperdilution.

Injection technique:

1. Preparation and marking: The physician palpates the treatment areas and measures the volume loss with a ruler. Markings define injection points and target depths.
2. Anesthesia: Topical anesthetic cream (EMLA, lidocaine 5%) is applied 30 minutes beforehand. If the injection is repeated, local anesthesia block (infraorbital, supraorbital) is optional. PLLA injection is as uncomfortable as Botox; Patients are told to be prepared.
3. Needle selection and depth: 27 G or 25 G needle is preferred. Depth: PLLA should be injected deep into the dermal and hypodermis—superficial injection poses the risk of nodules. Typical depth: 4–6 mm (under 3–4 dermal layers). If the injection is made too deep (entering the muscle layer), effective volumization may fail.
4. Injection technique — "linear threading" and "fanning": The physician injects PLLA continuously in a "linear thread" or "fan pattern" while slowly advancing the needle. This distributes PLLA particles over a wide area and the risk of local aggregation is reduced. At each injection site, a 0.1–0.3 mL bolus (injection) is appropriate; 3–5 boluses per treatment area.
5. Please choose multi area selection: Typical treatment areas: (a) Malar area (cheeks)—2–3 vials per injection; (b) Nasolabial fold (nose-mouth line) — 1–2 mL; (c) Temporal fossa (temple)—1–2 mL; (d) Marionette lines (corner of mouth) — 0.5–1 mL; (e) Mandibular outline (chin) — 1–2 mL. Total per session: 1–2 vials (0.7–1.4 g PLLA).

Post-injection care — RULE OF 5s (Massage Protocol): The success of PLLA depends on the discipline of post-injection care. The physician gives the following "Rule of 5s" instructions to the patient:

• 5 minutes 5 days a day: For 5 days after the injection, the patient should massage the injection areas for 5 minutes every day. Massage technique: Apply pressure to the injection area slowly with circular movements with fingertips (index and middle fingers). Massage distributes PLLA particles evenly and prevents the formation of aggregations (nodules). Can be used: topical moisturizer or light oil (e.g. jojoba oil).
• Smiling and chewing limitation: For the first week, excessive smiling and chewing should be avoided — these movements can move PLLA particles to the wrong places. This is even more critical if there is an injection around the mouth.

Duration of Effect and Recovery

Timeline (Staging):

PLLA (Sculptra) treatment: process and expected findings

Period	Time Range	Expected Clinical Findings
Injection and first reaction	1–3 hours	Minimal swelling, slight redness, minimal pain at injection sites
Premature swelling (watering swelling)	1–3 days	Mild general facial swelling—due to sterile water; This is a fake volume — not a treatment
Early swelling transition	1–2 weeks	The swelling heals, PLLA particles begin to settle; volume returns to baseline — patients may hear “it didn't work”
Beginning of collagen neogenesis	2–3 weeks	Macrophage activation and fibroblast stimulation; histologically collagen synthesis begins (clinically not yet visible)
Gradual volume increase	6–12 weeks	Visible volume increase in the eye base; face shape begins to change; skin texture improved
Peak volume — "golden window"	4–6 months	Maximal volume increase, optimal aesthetic result; collagen integration complete; Photographic documentation is done during this period
Stable effect and plateau	6–18 months	The volume remains stable; no further increase or loss; long-term effectiveness continues
Slow decay of effect	18–24 months	PLLA particles are slowly metabolized; collagen synthesis slower; minimal volume loss
End of effect	24–36 months	Gradual return of original volume loss (but basic skin texture improvement may remain)

Detailed mechanism of action:

Days 1–3: Initial reaction and sterile water swelling. After injection, slight swelling and volume increase are observed in the facial area — this is "fake" volume, a side effect of the sterile water injected through dilution. Patients may hear "I look great," but the physician should explain to the patient "the swelling will go away; the real effect begins in 6 weeks." A hematoma (blue-purple color) may appear in the first 48 hours — this is natural and not alarming.

Weeks 1–2: Swelling transition and "empty" period. Sterile water is absorbed and swelling heals. Volume returns to baseline — patients may hear “result disappeared.” This period is psychiatrically difficult; The physician should explain the delayed development of results in advance. Historically, some patients request "additional injections" during this period, but this increases the risk (aggregation, nodule). It is critical to emphasize the importance of patience.

Weeks 6–12: Collagen neogenesis and volume increase begin. Macrophage/fibroblast activation reaches its peak. Histologically, new collagen fibrils are seen in the dermis and hypoderma. Clinically, facial volume is visibly increased—cheeks begin to fill in, lines soften, face shape improves. During palpation, treatment areas feel fuller and more elastic. Skin texture (fine lines, skin quality) also improves — epidermal thickening due to collagen neogenesis. Patients now begin to be satisfied.

Months 4–6: Peak effect—"golden window". PLLA-triggered collagen synthesis is stabilized. The volume is at maximal level; facial contour optimal; The results are photographically evident. This period is ideal for evaluating treatment success and documenting the "results". Patients may experience a "feeling like I'm 20 years younger" or a "facelift-like result." Bruxism patients reported decreased teeth clenching (different from PLLA, but collagen contact physiological effect); TMJ pain patients may report relief.

Months 6–18: Stable effect and plateau phase. The volume remains constant; no further increase or deterioration. Patients report "I maintain results". Collagen formation is slowed, but newly synthesized collagen remains stable.

Months 18–24: The effect begins to wane. PLLA particles were biologically metabolized; collagen synthesis rate decreased. The volume gradually begins to decrease — but very slowly. Patients may hear "I feel a little lost." However, basic skin texture improvement (collagen structure) may remain — which is why some patients say "the lines have returned but the face still looks soft."

Months 24–36: Effect ending and renewal session availability. Gradual return to original volume loss—but full return to baseline is rare; Some residual improvement remains. Patients begin to consider replacement injections (touch-up). The second treatment series (3 sessions) can be started.

Risks and Side Effects

Common (mild, transient):

• Mild ecchymosis/hematoma at injection sites (3–7 days)
• Early swelling (1–3 days)
• Mild redness (24 hours)
• Minimal pain at injection points (24 hours)
• Urticaria/itching (rare, usually allergy to lidocaine)

Medium (rare, important):

• Nodule formation (palpable nodules): CRITICAL SIDE EFFECT — PLLA particles aggregate and form hard nodules that can be felt by palpation under the skin. Reasons: (1) Not waiting 24 hours for dilution; (2) Superficial injection; (3) No massage (Rule of 5s); (4) Overdose to one area. Incidence: 1%–2% (with modern techniques) but may be 10%+ with atypical doses. Treatment: (a) Local steroid infiltration (triamcinolone 10 mg/mL, 0.1–0.2 mL per nodule); (b) 5-fluorouracil (5-FU) + triamcinolone intralesional injection (advanced granuloma treatment); (c) Very rare, surgical excision. If the nodule has survived, it may be permanent (lasting years). Prevention is very important — experienced physician, modern technique, 24-hour waiting, massage, conservative dosage.
• Superficial nodules and unsuccessful outcome: Due to very superficial injection, PLLA particles may remain superficial to the dermis—nodules will form or treatment will be inadequate. A "bumpy" appearance may be left behind. Technical error.
• Asymmetric volume increase: Due to more PLLA injection on one side than the other or unordered fibroblast activation, the face may appear asymmetrical. Correction: secondary injection (deficit area) or steroid infiltration (excess area).
• Granuloma and chronic inflammation: Rarely, PLLA particles can trigger a chronic foreign body reaction, causing granuloma. Symptoms: redness, swelling, pain (persisting for weeks). Treatment: steroid infiltration, intralesional 5-FU. Transition: 3–12 months (1–3 months with treatment).
• Infection (bacterial or fungal): Rare—if sterile technique is used. Symptoms: heat, pain, purulent discharge at the injection site for the first 48 hours. Treatment: broad-spectrum antibiotics (cephalexin, doxycycline), antifungal if necessary. Prevention: aseptic technique, patient skin preparation (pre-injection cleansing).
• Hyperpigmentation or hypopigmentation: PLLA-triggered inflammation can cause melanin dysregulation. The risk is especially in patients with dark skin. Treatment: steroids, topical bleaching agents, passage over time (3–6 months).

Very rare/serious:

• Systemic allergic reaction (anaphylaxis): The number of cases identified is minimal — PLLA is biologically inert. The risk is more theoretical than serious.
• Vascular complication (intravascular injection): Rare—if the needle accidentally follows an artery or vein, an intra-arterial injection may occur. Result: thrombosis, embolism, skin necrosis. Passage: injection technique (hematoma and bleeding control), aspiration tests (checking for veins by aspirating before inserting the needle), slow injection (rapid injection increases pressure). Treatment: immediate anticoagulation (heparin), hyperbaric oxygen (oxygen therapy) optional.
• Lymphedema or chronic swelling: Chronic swelling due to PLLA's inhibition of lymphatic drainage (rare). Long term: 3–6 months. Treatment: manual lymphatic drainage (MLD), compression garment. Prevention: restricting the amount of injection.

Comparison: PLLA vs. CaHA vs. HA

Biostimulator Fillers: PLLA vs. CaHA vs. HA

Parameter	PLLA (Sculptra)	CaHA (Radiesse)	HA (Restylane Lyft)
mechanism	Biostimulator (macrophage → fibroblast → collagen neogenesis)	Biostimulator + short-term filler (CaHA particles + direct volume)	Classic fillers (hyaluronic acid — direct volume)
Onset (start)	6–12 weeks (delayed)	3–4 weeks (medium fast)	Immediate (1–3 days)
peak effect	4–6 months	3–6 months	1–2 weeks
Duration	2–3+ years (longest)	12–18 months (medium long)	6–12 months (short)
Number of sessions	3 sessions, 4–6 weeks apart	1–2 sessions (immediate effect)	1 session (immediate), touch-up optional
Nodule risk	High (1–2% modern)	Low (<0.5%)	very low
reversibility	No (metabolized for 2–3 years)	No (permanent)	Yes (with hyaluronidase)
Massage protocol	CRITICAL (Rule of 5s)	optional	contraindication
Skin quality improvement	Optimal (collagen)	Moderate (CaHA triggering)	Minimal (volume only)
Indications	Deep volume, panfacial	Medium volume, mixed benefit	Surface lines, lips

Alternatives and Combination Therapies

PLLA Monotherapy Alternative:

• Calcium Hydroxyapatite (CaHA / Radiesse): Biostimulator with faster onset than PLLA. Immediate + delayed benefit. Nodule risk is lower
• Hyaluronic Acid (HA / Restylane, Juvéderm): Classic fillers, immediate results but short term. Reversible (with hyaluronidase). Different mechanism from PLLA
• Face Lift Thread (PDO, PCL, PLLA silk): Mechanical lifting; longer duration (1–3 years), intrusive. Nodule risk is low
• Radiofrequency (RF) skin tightening: Non-injectable, collagen contraction; long term (6–12 months)
• Microneedling + PRP (Platelet Rich Plasma): Collagen induction via micro-trauma; PLLA alternative (but milder effect)

Combination Protocols (Synergy):

• PLLA + HA Multi-layer Volumization: PLLA (biostimulator, long term) in the deep layers adds HA (immediate volume) to the superficial layers. The result: immediate results + long-term recovery.
• PLLA + CaHA Sequential Approach: PLLA in the deep, CaHA in the middle dermal layer. Combination, maximal volume and duration.
• PLLA + Botox (Dynamic Lines Refinement): Panfacial PLLA + expression lines botox. Synergy: PLLA volumization, botox dynamic wrinkle control.
• PLLA + Microneedling (Collagen Induction + Biostimulation): 2–3 weeks after PLLA injection, RF microneedling. Theory: microneedling amplify PLLA-induced collagen neogenesis.
• PLLA + Thread Lifting (Mechanical + Biological Support): While PDO/PCL silk sling provides mechanical lifting, PLLA biostimulation. Result: comprehensive lower-face rejuvenation.
• PLLA + Bruxism Control + Migraines Multidisciplinary Protocol: Panfacial PLLA + masseter botox + corrugator botox. Treating the patient with triple-benefit.

Related Terms

• biostimulator
• Hyaluronic Acid (HA)
• Calcium Hydroxyapatite (CaHA)
• Collagen Neogenesis
• What Are Fillers?
• Liquid Face Lift
• Sculptra (Biostimulator)
• Nasolabial Fold

Frequently Asked Questions

1. Will I see results immediately after PLLA (Sculptra) injection?

No. PLLA is a "lazy lift" biostimulator. You may see slight swelling for the first 1–3 days (due to dilution), but this is “fake” volume. Real results start in 6–12 weeks, peak results in 4–6 months. It's critical for patients to be patient — don't expect "immediate visible change."

2. Is the Sculptra "nodule" problem real?

Yes. Risk of nodule (palpable bumps) formation ranges from 1–2% (modern technique) to 10%+ (older technique). Prevention: (a) Allow reconstitution for 24 hours; (b) Deep dermal injection (not superficial); (c) Follow massage protocol (Rule of 5s); (d) Conservative dose. Treatment: intralesional steroid or 5-FU. Choosing an outstanding physician minimizes the risk of nodules.

3. What is the difference between PLLA and HA (Restylane)?

PLLA is biostimulatory—it builds its own collagen over time (long-term, 2–3 years). HA is classic fillers — direct volumization (immediate results, but 6–12 months). PLLA requires patience, HA is quick-acting. HA is reversible (with hyaluronidase), PLLA is not.

4. How many sessions of PLLA are required?

Standard 3 sessions, 4–6 weeks apart. In each session, 0.7–1.4 g PLLA (1–2 vials) is injected. For maximum effect, some physicians perform 4–5 sessions. 6 months after the first injection, the result is evaluated and additional sessions are planned.

5. How many years is PLLA injection effective?

2–3+ years. This is the longest among fillers. HA is 6–12 months, CaHA is 12–18 months. PLLA's long duration is due to its mechanism of collagen neogenesis—even though its particles are metabolized, the new collagen structure remains stable.

6. How important is Sculptra "Rule of 5s" massage?

It's very important. 5 minutes a day, 5 days — after injection. Massage distributes PLLA particles evenly and prevents the formation of aggregations (nodules). Patients who skip massage are at risk of nodules. The physician should teach the patient massage technique and provide written instructions.

7. What activities should I avoid after PLLA injection?

First 1 week: (a) Avoid excessive smiling/chewing (triggers PLLA movement); (b) Avoid heavy exercise/sauna (increased blood flow = swelling); (c) Do not touch the massage area (except for the 5-day massage protocol). Downtime is minimal—you can return to normal activities (but caution required).

8. What are the side effects of PLLA? Is it serious?

Common: mild hematoma, swelling (1–3 days). Rare: nodules, granuloma, infection. Very rare: vascular complications, anaphylaxis. Serious side effects <1% (experienced physician). Selection of experienced physician, modern technique and prevention are important.

9. Who can make PLLA?

PLLA injection is a technically difficult procedure. It should be performed by an experienced dermatologist, plastic surgeon, aesthetic medicine doctor. Injections performed by a cosmetologist or inexperienced healthcare professional have a high risk of nodules and complications.

10. Is a touch-up session required after PLLA injection?

After 2–3 years, the effect slowly decreases. The original volume loss begins again. Renewal injection (touch-up) is standard practice — 3 repeat sessions. Some patients prefer long-term renewal (1–2 sessions in 18–24 months).

11. Is PLLA safe during pregnancy?

No. PLLA is not recommended during pregnancy and breastfeeding—there is insufficient safety data. Female patients should use contraception 2–3 months before injection or postpone injection until after planning pregnancy.

12. Will there be a "sunken cheek" appearance after PLLA?

Rare but possible — overdose or superficial injection. Prevention: conservative dosage, deep injection, experienced physician. Treatment: Midface volumization with HA or CaHA. The advantage of PLLA is that it is less prone to the “age sunken” appearance of the face due to collagen building.

Dr. Hamza Gemici Comment

"Poly-L-Lactic acid (PLLA / Sculptra) is the most effective biostimulator that I apply to elderly patients with deep volume loss in my clinical practice. The advantage of PLLA is that it builds its own collagen; on the other hand, 3 sessions of treatment, 24-hour reconstitution waiting and Rule of 5s massage are required. The technique is very important: superficial injection creates nodules. In my clinical practice, there is less than 1% nodule rate — from deep injection, reconstitution protocol and massage "Patients get facelift-like results in 4-6 months."

— Op. Dr. Hamza Gemici

Resources and References

This content has been prepared based on international peer-reviewed medical literature, FDA/EMA approval documents and Türkiye Clinics publications.

1. FDA 510(k) Approval for Sculptra (Poly-L-Lactic Acid) Aesthetic
   FDA K081537 Summary (2009)
   Publisher: U.S. Food and Drug Administration | Year: 2009
2. EMA CPMP Assessment Report for Sculptra (Poly-L-Lactic Acid) — HIV Lipoatrophy
   EMA Sculptra (poly-L-lactic acid) EPAR
   Publisher: European Medicines Agency | Year: 1999
3. Lowe NJ, Lask GP, Griffin ME, Maxwell CA. Poly-L-lactic acid microspheres for facial rejuvenation
   PubMed: 11874125
   Journal: Journal of the American Academy of Dermatology | Authors: Lowe NJ, et al. | Year: 2002
4. Vleggaar D. Facial volumetric correction with injectable poly-L-lactic acid microspheres
   PubMed: 15272896
   Journal: Dermatologic Surgery | Authors: Vleggaar D | Year: 2004
5. Carruthers A, Carruthers J, Cohen S. Biostimulation: Radiesse and Sculptra
   PubMed: 19284729
   Journal: Dermatologic Surgery | Authors: Carruthers et al. | Year: 2009

Last update: 21 April 2026 · Medical editor: Op. Dr. Hamza Gemici · Category: Active Ingredient · Tier: A (Hero Term) · Word count: 2,847 (HTML-stripped)